On Apr. 6, 2020, Mateon Therapeutics announced that it  has delivered the requisite testing results to Golden Mountain Partners (GMP) confirming the applicability and potential use of OT 101 for the treatment of COVID-19. OT-101 exhibited potent activity against both COVID-19 and SARS with a robust safety index of >500. This is in accordance with the Supplement Research and Services Agreement with GMP executed on March 23, 2020, and GMP has accepted the testing results.

In addition, Mateon has submitted a Pre-Investigational New Drug (Pre-IND) application package to the FDA to allow the referencing of OT 101’s oncology IND in order to streamline the IND submission for OT 101 against COVID-19. Mateon is expecting to complete the IND submission thereafter.

The mechanism of action (MOA) for OT 101 against COVID-19 includes: 1) Inhibition of cellular binding, 2) Inhibition of viral replication and 3) Suppression of viral induced pneumonia. Based on OT-101’s MOA, Mateon anticipates that OT 101 would also be useful for future viral epidemics.